Equities researchers at StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX – Get Rating) in a research report issued on Sunday. The firm set a "hold" rating on the biotechnology company's stock.
Jaguar Health Stock Performance
Shares of Jaguar Health stock opened at $0.17 on Friday. Jaguar Health has a 12-month low of $0.15 and a 12-month high of $2.66. The company has a market cap of $20.00 million, a price-to-earnings ratio of -0.15 and a beta of 1.65. The company has a current ratio of 1.02, a quick ratio of 0.73 and a debt-to-equity ratio of 8.47. The company's 50-day moving average price is $0.25 and its 200-day moving average price is $0.37.
Get Jaguar Health alerts:Jaguar Health (NASDAQ:JAGX – Get Rating) last announced its quarterly earnings results on Monday, August 22nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. Jaguar Health had a negative net margin of 652.35% and a negative return on equity of 486.62%. The firm had revenue of $2.92 million for the quarter. On average, equities analysts expect that Jaguar Health will post -0.67 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new position in shares of Jaguar Health in the first quarter worth approximately $1,079,000. Virtu Financial LLC increased its position in shares of Jaguar Health by 76.1% in the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company's stock worth $162,000 after purchasing an additional 99,073 shares during the last quarter. Millennium Management LLC increased its position in shares of Jaguar Health by 152.3% in the second quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company's stock worth $157,000 after purchasing an additional 321,795 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Jaguar Health by 507.3% in the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company's stock worth $120,000 after purchasing an additional 141,796 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Jaguar Health by 153.3% in the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 33,148 shares during the last quarter. 7.40% of the stock is currently owned by institutional investors.Jaguar Health Company Profile
(Get Rating)
Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
See Also
- Get a free copy of the StockNews.com research report on Jaguar Health (JAGX)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.